Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Controlled Biomarker Study Evaluating the Anti-angiogenic Activity of Sunitinib in Hormone Refractory Prostate Cancer Patients Treated by Docetaxel

NCT00795171 is registered in ClinicalTrials.gov with Medical University of Vienna as lead sponsor.

NCT NCT00795171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00795171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Controlled Biomarker Study Evaluating the Anti-angiogenic Activity of Sunitinib in Hormone Refractory Prostate Cancer Patients Treated by Docetaxel
Lead sponsor
Medical University of Vienna
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2008
Completion date
July 31, 2011
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hormone refractory prostate cancer